Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVID-19 booster programme

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

NHS England winter flu and COVID-19 vaccine programmes start early

Those who are eligible will be offered a vaccination from 18 September 2023 onwards

- PMLiVE

MIT researchers design more powerful RNA vaccines for COVID-19

The new type of RNA vaccine was shown to produce a stronger immune response at a lower dose

- PMLiVE

AstraZeneca shares positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE

Bavarian Nordic’s COVID-19 booster ‘not suitable’ for emerging variants

Results showed that ABNCoV2 was not as effective against the circulating XBB.1.5 variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links